Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-11 am EDT			5-day change	1st Jan Change
180.70 ^DKK	-1.66%		+4.36%	-4.57%

Jul. 10	Bavarian Nordic Bags DKK200 Million Order for Smallpox/Mpox Vaccine	MT
Jul. 09	Bavarian Nordic Secures Vaccine Order Worth Over 200 Million Danish Kroner from Unnamed European Country	FW

Stocks, dollar gain as investors look for US-China trade talk progress

Published on 06/10/2025 at 04:36

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bavarian Nordic A/S

Bavarian Nordic Bags DKK200 Million Order for Smallpox/Mpox Vaccine	Jul. 10	MT
Bavarian Nordic Secures Vaccine Order Worth Over 200 Million Danish Kroner from Unnamed European Country	Jul. 09	FW
Bavarian Nordic enters smallpox/mpox vaccine supply contract with European country	Jul. 09	RE
Bavarian Nordic A/S Enters New Smallpox/Mpox Vaccine Supply Contract with European Country	Jul. 09	CI
Bavarian Nordic Begins Mpox/Smallpox Vaccine Trials in Vulnerable Populations	Jun. 26	MT
Valneva Lands Exclusive Commercialization Deal for Three Vaccines in Germany	Jun. 26	MT
Bavarian Nordic to Sell US Priority Review Voucher for $160 Million	Jun. 18	MT
Bavarian Nordic is selling the PRV for $160 million.	Jun. 18	FW
Bavarian Nordic Announces Sale Of Priority Review Voucher For $160 Mln	Jun. 18	RE
Bavarian Nordic Announces Sale Of Priority Review Voucher For USD 160 Million	Jun. 18	RE
Bavarian Nordic Begins Chikungunya Vaccine Study in Children	Jun. 12	MT
Bavarian Nordic initiates Phase 3 study of chikungunya vaccine in children	Jun. 12	FW
Bavarian Nordic Starts Phase 3 Study Of Chikungunya Vaccine In Children	Jun. 12	RE
Stocks, dollar gain as investors look for US-China trade talk progress	Jun. 10	RE
Bavarian Nordic A/S, Q1 2025 Earnings Call, May 09, 2025	May. 21
US CDC accepts recommendations for chikungunya vaccines	May. 21	RE
US CDC approves recommendations for chikungunya vaccines	May. 21	RE
Bavarian Nordic A/S Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 08:00 AM	May. 20
Denmark says Trump's drug pricing order is a step in the wrong direction	May. 16	RE
SEB raises target price for Bavarian Nordic to DKK 275 (250), reiterates buy recommendation - BN	May. 12	FW
Europe's STOXX 600 up, Germany's DAX at record peak on trade deal optimism	May. 09	RE
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 09	CI
Bavarian Nordic increases sales and profit - repeats forecast	May. 09	FW
Bavarian Nordic Maintains 2025 Outlook	May. 09	RE
Tranche Update on Bavarian Nordic A/S's Equity Buyback Plan announced on May 8, 2024.	May. 09	CI

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (96.1%) and services (3.9%). Net sales are distributed geographically as follows: the United States (47.3%), Germany (17%), Canada (8.6%), France (4.7%), Saudi Arabia (4.6%), Belgium (3.8%), Singapore (2.2%), and other (11.8%).

Employees

1,645

Sector

Pharmaceuticals

Calendar

Aug. 21 - Q2 2025 Earnings Release

More about the company